Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical research trials and Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis. Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis clinical trial. Participants typically obtain the most effective healthcare available for their Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "I" Clinical Trials Conditions > Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis



Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

For Condition: Aspergillosis
Status: Recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant). This study will seek to enroll patients (16 years of age or older) with invasive aspergillosis infections (involving organs or deep tissues) who are failing or could not tolerate standard antifungal therapy. Your doctor will make this determination based upon specific study criteria. Patients that fulfill all study criteria will be treated daily with both the investigational drug and another antifungal agent. The choice of the other agent is up to your doctor. This investigational drug is approved for the treatment of invasive aspergillosis by itself. The safety and efficacy of this investigational drug, in combination with other agents is not known.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: - Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy. - The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU hCG prior to enrollment.
Total Enrollment: 

Location and Contact Information:

Call for Information *Recruiting*
Ft. Sam Houston,  Texas,  78234-6200
United States
Recruiting  

Call for Information *Recruiting*
Birmingham,  Alabama,  35294
United States
Recruiting  

Call for Information *Recruiting*
Rochester,  New York,  14642
United States
Recruiting  

Call for Information *Recruiting*
Maywood,  Illinois,  60153
United States
Recruiting  

Call for Information *Recruiting*
Charlottesville,  Virginia,  22908
United States
Recruiting  

Call for Information *Recruiting*
Detroit,  Michigan,  48201
United States
Recruiting  

Call for Information *Recruiting*
Minneapolis,  Minnesota,  55455
United States
Recruiting  

Call for Information *Recruiting*
Buffalo,  New York,  14263
United States
Recruiting  

Call for Information *Recruiting*
Tucson,  Arizona,  85724
United States
Recruiting  

Call for Information *Recruiting*
Boston,  Massachusetts,  02115
United States
Recruiting  

Call for Information *Recruiting*
Augusta,  Georgia,  30912-3125
United States
Recruiting  

Call for Information *Recruiting*
Minneapolis,  Minnesota,  55417
United States
Recruiting  

Call for Information *Recruiting*
Houston,  Texas,  77030-4095
United States
Recruiting  

Call for Information *Recruiting*
Salt Lake City,  Utah,  84132
United States
Recruiting  


Additional Information:
Study ID Numbers:
  0121FI; 
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076869

Other Aspergillosis Studies:
1. Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

2. Study of FK463 for the Treatment of Invasive Aspergillosis

3. An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

4. A Safety & Effectiveness Study of Intravenous Anidulafungin with AmBisomeĀ® for Treatment of Invasive Aspergillosis (IA).

5. Voriconazole to Prevent Systemic Fungal Infections in Children

Related Studies:

Other Aspergillosis Clinical Trials
Other Texas Clinical Trials
Other Ft. Sam Houston Clinical Trials

Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

Modify your Search

  Other Aspergillosis Clinical Trials
  Other Texas Clinical Trials
  Other Ft. Sam Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103